Document Detail

Methotrexate in psoriatic arthritis.
MedLine Citation:
PMID:  12463453     Owner:  NLM     Status:  MEDLINE    
Methotrexate (MTX) is a folic acid analogue with antiproliferative and antiinflammatory effects. In the past several years, MTX has become the most commonly used agent in patients with severe, destructive psoriatic arthritis (PsA), with positive clinical results. Liver changes and serum enzyme level increases do not seem to be a major problem in PSA patients treated with MTX. In addition, PSA patients treated with low-dose MTX were not associated with pulmonary fibrosis as evaluated by means of sensitive imaging techniques and pulmonary function tests. The concomitant use of folic acid reduces both the frequency of serum liver enzyme level increases but also the efficacy of MTX by competing with the folate receptors.
M Cutolo; B Seriolo; C Pizzorni; C Craviotto; A Sulli
Related Documents :
21142823 - Range of motion and strength after surgery for brachial plexus birth palsy.
19200133 - Complete blood count reflects the degree of oesophageal varices and liver fibrosis in v...
20691343 - Editor's comment and q&a dehiscence and fenestration in patients with class i and class...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical and experimental rheumatology     Volume:  20     ISSN:  0392-856X     ISO Abbreviation:  Clin. Exp. Rheumatol.     Publication Date:    2002 Nov-Dec
Date Detail:
Created Date:  2002-12-04     Completed Date:  2003-05-13     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8308521     Medline TA:  Clin Exp Rheumatol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  S76-80     Citation Subset:  IM    
Research Laboratory, Division of Rheumatology, Department of Internal Medicine, University of Genova, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antirheumatic Agents / adverse effects,  therapeutic use*
Arthritis, Psoriatic / drug therapy*
Methotrexate / adverse effects,  therapeutic use*
Practice Guidelines as Topic
Reg. No./Substance:
0/Antirheumatic Agents; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Disease-modifying antirheumatic drug therapy for psoriatic arthritis.
Next Document:  Standard and innovative therapy of psoriasis.